Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.
Seimetz
Diane
D
Fresenius Biotech GmbH, Frankfurter Ring 193a, D-80807 München, Munich, Germany. diane.seimetz@fresenius-biotech.com
Lindhofer
Horst
H
Bokemeyer
Carsten
C